Main menu

Manchester, UK, February 19th 2013 – F2G Limited, the UK-based antifungal drug discovery and development company, today announced the appointment of Dr. John H. Rex to the Company’s Board as an Independent Director. Dr. Rex is a distinguished research scientist and recognized as an opinion leader in the field of infectious disease therapy and, in particular, for antifungal agents. He has a BA in Biochemistry from Rice University, an MD from Baylor College of Medicine, and is Vice President and Head of Infection, Global Medicines Development, at AstraZeneca.

Prior to joining AstraZeneca in 2003, Dr. Rex was Professor of Medicine at the University of Texas Medical School-Houston. Dr. Rex has been the Industry Representative on the US FDA Anti-Infective Drug Advisory Committee (2007-2011), is Vice-Chair of the Consensus Committee on Microbiology for the Clinical Laboratory Standards Institute (CLSI, formerly NCCLS), is a Highlights Advisor for Nature Reviews Microbiology, is a member of the Wellcome Trust Seeding Drug Discovery Committee, serves on several editorial boards, was formerly an Editor for Antimicrobial Agents and Chemotherapy, and is an Emeritus Editor for www.doctorfungus.org, a non-profit web site devoted to dissemination of information about medical mycology.

Dr. Richard White, Executive Chairman of F2G, commented, “We are delighted to have John join the board and look forward to benefiting from the breadth and depth of his knowledge and experience in the antifungal arena”.

Dr. Rex will become a key member of the Board’s Science Committee, chaired by Dr. Raj Parekh, who remarked “John’s counsel will be critical in helping F2G successfully develop its totally novel class of drugs to treat Aspergillosis – a potentially life-threatening infection usually affecting the lungs.”

Dr. Rex, who will continue his role at AstraZeneca, added, “This is an exciting time to be involved with F2G and participate in bringing a new class of antifungal agents into clinical practice. Aspergillosis remains a serious disease in an era of increasing resistance with few treatment options. In addition, I view this opportunity to work with F2G as a chance to collaborate and bring insights from the biotechnology sector into the anti-infective development work at AstraZeneca.”

About F2G Ltd:

Based in Manchester, UK, F2G Ltd is dedicated to the discovery and development of new and clinically superior drug classes to treat life-threatening systemic fungal infections in at-risk patient populations. This is a growing health risk for which there are currently limited treatment options and for which demand is increasing globally Market growth is expected to increase with the emergence of new clinical indications in allergies and asthma. For more information visit www.f2g.com

Manchester, UK, Sept 5th 2012 – F2G Limited, an antifungal drug discovery and development company, today announced the completion of a $30 million equity financing round in which two new investors (Advent Life Sciences and Novartis Bioventures) joined the existing syndicate (Sunstone Capital, Merifin Capital, K Nominees, and Astellas Venture Fund). These funds will be used to select a clinical candidate from the F3 series of advanced preclinical analogs and proceed to first in man studies. The F3 series represents a proprietary group of compounds with highly potent and selective activity against Aspergillus species and other moulds, which act via a totally novel mechanism. Aspergillus infections are a serious threat in immune-compromised patient populations and result in a high rate of mortality even with the most effective treatment currently available. Dr Richard White, chairman of F2G, commented, “We are delighted to welcome two top tier investors into F2G. We now have a first class international syndicate, including the venture arms of two major pharmaceutical companies”.

Shane Kelly, previously the CEO, is leaving the company to pursue another opportunity. Dr White will assume the expanded role of Executive Chairman and noted “We would all like to thank Shane for his tireless and steadfast management of the company over the last 10 years and for bringing us to this successful juncture. We wish him well in his new venture”

Dr Raj Parekh of Advent and Dr Anja König of Novartis Venture Funds will both be joining the Board of F2G. Raj Parekh, General Partner at Advent said, “The F2G molecules show a compelling and novel profile and have the genuine potential to be first- and best- in-class agents for the treatment of invasive aspergillosis, which remains a serious unmet medical need. We look forward to working with Richard and the team to bring these molecules to an early clinical evaluation.”

About F2G Ltd:

Based in Manchester, UK, F2G Ltd is dedicated to the discovery and development of new and clinically superior drug classes to treat life-threatening systemic fungal infections in at-risk patient populations. The antifungal market is currently estimated at over 6 billion dollars annually and is growing steadily year on year. Market growth is expected to increase with the emergence of new clinical indications in allergies and asthma. The company has impressive internal capabilities, employing a core team of scientists with a unique understanding of the antifungal arena, supported by an experienced management team. For more information visit www.f2g.com

Manchester, UK, 11 September 2010 – F2G Limited, the UK based antifungal drug discovery and development company, today announced the appointment of Dr Michael R. Hodges to the Company’s Board of Directors.

Michael R Hodges, M.D., BSc., MRCP (UK) has 20 years of biopharmaceutical development experience and has worked in both biotechnology and large pharmaceutical companies. Whilst at Pfizer Inc. Dr. Hodges was the development team leader for Vfend™, the gold standard therapy for invasive aspergillosis, as well as working on the Eraxis™ and Diflucan™ antifungal programs. In addition Dr. Hodges worked on the Zithromax™ and HIV portfolio development programs.

Prior to joining industry at Pfizer Inc. in 1990, Dr. Hodges practiced internal medicine in London, UK. 1989-90 he held an appointment through the Medical Research Council (UK), at St Thomas’ Hospital, London, HIV clinical trials unit. From 1992 to 2001 he held honoree positions with East Kent Hospitals University NHS Foundation Trust.

Shane Kelly, Chief Executive of F2G commented “It is with great pleasure that we announce that Michael Hodges has accepted our invitation to join the Board. His track record in the successful development and transition of antifungals to market will be invaluable as F2G continues to advance its portfolio of antifungal agents.”

Dr Richard White, Chairman of the Board added “We are delighted to welcome Michael to the Board. His knowledge and experience in the antifungal sector will be a considerable asset to F2G and I look forward to working with him towards the further development of F2G’s antifungal programs.”

Commenting on his appointment, Dr Michael Hodges said “I am delighted to be joining the Board of Directors, especially at such an exciting time for the company as they move their series of novel antifungal drug candidates into the clinic”.

About F2G Ltd:

Based in Manchester, UK, F2G Ltd is dedicated to the discovery and development of new and clinically superior drug classes to treat life-threatening systemic fungal infections in at-risk patient populations. The antifungal market is currently estimated at over 6 billion dollars annually and is growing steadily year on year. Market growth is expected to increase with the emergence of new clinical indications in allergies and asthma.

The company has impressive internal capabilities, employing a core team of scientists with a unique understanding of the antifungal arena, supported by an experienced management team. F2G operates a flexible business model, building value through the development of a balanced portfolio of antifungal assets across multiple validated TPPs.

For more information visit www.f2g.com

Contact:

Shane Kelly
Chief Executive Officer
F2G Ltd
Tel: (+44) 0161 785 1271
Fax: (+44) 0161 785 1273
Email: shanekelly@f2g.com

Manchester, UK, 23 February 2010 – F2G Limited, the Manchester UK based antifungal drug discovery and development company, today announced the appointment of Dr Richard J. White as Chairman of the Company’s Board of Directors. Dr White has served as a non-executive director of F2G Ltd since April 2006.

F2G also announced the appointment of a new non-executive director, Dr Sten Verland of Sunstone Capital A/S.

“I congratulate Richard on his appointment as Chairman” said Shane M. Kelly, Chief Executive of F2G Ltd. “Richard has a wealth of experience in infectious disease drug discovery gained within Biotech and Pharma. He has been a tremendous asset to the Company during his time on the Board and I look forward to working with him towards the further development of F2G Ltd. The Board also welcomes Dr Sten Verland, whose proven expertise in building successful businesses will be a valuable addition to the team.”

Dr Richard J. White commented “This an exciting time for F2G as our lead program progresses to clinical testing and I eagerly anticipate working closely with the other Board members”.

About F2G Ltd:
Based in Manchester, UK, F2G Ltd is dedicated to the discovery and development of new and clinically superior drug classes to treat life-threatening systemic fungal infections in at-risk patient populations. The antifungal market is currently estimated at over 6 billion dollars annually and is growing steadily year on year. Market growth is expected to increase with the emergence of new clinical indications in allergies and asthma.

The company has impressive internal capabilities, employing a core team of scientists with a unique understanding of the antifungal arena, supported by an experienced management team. F2G operates a flexible business model, building value through the development of a balanced portfolio of antifungal assets across multiple validated TPPs.

For more information visit www.f2g.com

Contact:

Shane Kelly
Chief Executive Officer
F2G Ltd
Tel: (+44) 0161 785 1271
Fax: (+44) 0161 785 1273
Email: shanekelly@f2g.com

Manchester, England, 11th February 2009 – F2G Limited, the Manchester UK based antifungal drug discovery and development company, today announced the appointment of Dr Tony Kennedy as Chief Scientific and Development Officer. In this capacity, Dr Kennedy will be responsible for the progression of F2G’s novel antifungal portfolio from discovery through development and the consolidation of the F2G development function.

Prior to joining F2G, Dr Kennedy led a number of anti-infective global development teams in Roche and SmithKline Beecham including the Roche-Gilead Tamiflu flu antiviral global team which advanced the molecule from discovery to registration in just over 3 years. Tony was then appointed as Roche Global Head of Project Management and served as a member of Roche’s Strategic Marketing Management Team and its Development Committee before being recruited to lead the Development Functions at UK Biotechs Trigen and Vantia.

Dr Kennedy commented “I am delighted to be joining F2G and working with the
outstanding team who have discovered a completely new class of antifungal agents with outstanding efficacy in preclinical efficacy models. These agents have the potential to address the high unmet medical needs in invasive fungal disease. I look forward to expediting the progression of our leads to clinical study and patient trials.”

The F2G Management Team is consolidated by the promotion of Dr Mike Birch, VP Operations, to the position of Chief Operating Officer. Dr Birch has a strong background expertise in antifungal research and has successfully discharged management roles of increasing responsibility for the company prior to his new appointment.

Dr Lloyd Payne, F2G’s Chief Scientific Officer, is leaving the company to pursue new career opportunities but will remain a consultant to F2G Ltd. Commenting on the changes, Shane Kelly, Chief Executive said “F2G is now poised to advance its lead antifungal assets into clinical development and we are restructuring the management team to equip ourselves for the challenges ahead. We are delighted to welcome Tony to our world-class team. He has extensive drug development experience and a successful track record of fast tracking projects through development. I am confident that his expertise will accelerate the development of our compounds.

Mike Birch, our new COO, has played a pivotal role in the development of the company and in building its strong relationships with the antifungal community both within Pharma and the clinic which will serve us well in the period ahead.

I would like to thank Dr Lloyd Payne for serving the company with distinction as CSO. The company wishes him well in his future career.”

About F2G Ltd:
F2G Ltd is dedicated to the discovery and development of new and clinically superior drug classes to treat life-threatening systemic fungal infections in at-risk patient populations. The antifungal market is currently estimated at over five and a half billion dollars annually and is growing steadily year on year. Market growth is expected to increase with the emergence of new
clinical indications in allergies and asthma.

For more information visit www.f2g.com

Contact:
Shane Kelly
Chief Executive Officer
F2G Ltd
Tel: (+44) 0161 785 1271
Fax: (+44) 0161 785 1273
Email: shanekelly@f2g.com

Find us

Contact us

F2G Ltd
Lankro Way
Eccles
Manchester
United Kingdom
M30 0LX

Telephone | +44 (0)161 785 1270
Fax | +44 (0)161 785 1273
email |  contact@f2g.com


Registered in England and Wales. Company Registration No. 03578625, VAT Reg No. 712680645.